Pramiracetam, a laboratory-made memory compound, is a licensed medicine for age-related memory problems in a few European countries and an unapproved product sold online elsewhere. Evidence is thin and dated: small studies show memory gains in people with existing memory problems, especially after brain injury, none in Alzheimer's, and little information for healthy adults. Side effects appear mostly mild; kidney impairment, anti-clotting medication (possible bleeding) and product quality raise concerns. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum creatinine with eGFR | Creatinine about 0.7–1.3 mg/dL (men), 0.6–1.1 mg/dL (women) | Safety check: reduced kidney function slows elimination |
| ALT and AST | ALT about 7–56 U/L, AST about 10–40 U/L | Safety check: liver disease is a contraindication |
| INR (warfarin users only) | About 0.8–1.2 off anticoagulants; therapeutic target set by the prescriber | Safety check: detects added bleeding risk with anticoagulants |
| Cognitive test score (e.g., MoCA) | No established target; change from own baseline | Expected to change: the intended memory benefit |
Cadence: Baseline kidney, liver and cognitive tests (plus INR for warfarin users); cognitive re-test at 4 and 8 weeks; INR at 1–2 weeks for warfarin users; creatinine with eGFR every 6–12 months during long-term use, more often in adults over 65